Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We see a very bright future for STAR-0215 as the potential first choice preventative HAE therapy |
| As noted, we believe that 310 could be a best-in-class and first choice treatment for atopic dermatitis |
| I think that when we talk with physicians, the community, the patients, working with our advocacy organizations, we get a lot of frankly positive feedback that the profile is something that is meaningful to patients with this disease, specifically the ability to administer in such a way that has the potential to potentially normalize the lives of people living with this disease that appears to be very attractive |
| And given that 310 is designed to be T cell preserving with low ADCC, we think it has the potential to have the best-in- class safety profile |
| And I think we all already have strong support from the community demonstrated by the enrollment that we've talked about with 215 |
| First choice to us means patients and treating physicians would choose our products because of their strong competitive efficacy, low treatment burden, and favorable safety and tolerability profile |
| Beyond atopic dermatitis, we believe that target OX40 has strong potential in a broad range of additional indications |
| We think that STAR-0215 is very well positioned to be the first choice preventive treatment to help improvise the lives of patients changings |
| One, as Chris shared earlier, we have compelling data from our 1a trial that supports its potential best-in-class profile |
| We also saw favorable safety and tolerability with 215 and no serious adverse events for discontinuations due to an adverse event |
| Three, STAR-0215 has the potential to provide rapid and durable protection against HAE attacks |
| We've had an exciting few months at Astria and are in a strong position to close out the year |
| Ultimately, we are very pleased to see that these results support both every three and every six-month dosing strategy for a potential HAE preventative therapy with robust attack suppression and low treatment burden |
| I think the good news for us is that both physicians and patients are very excited about both dosing options |
| But I do believe that we'll continue to publish hopefully very impressive encouraging data that both physicians and patients will be interested in |
| The potential benefit here is robust and sustained responses across a broad range of AD |
| Yes, we're very excited about the ability to demonstrate some initial proof-of- concept data in patients |
| So in summary, we're excited about the potential of STAR-0215 becoming a first choice preventative treatment for HAE patients for the following reasons |
| All three of these programs have seen promising clinical efficacy results through Phase 2b in atopic dermatitis |
| Two, STAR-0215's mechanism of action and modality are proven safe and effective in HAE, as demonstrated by the current market leader |
| In both scenarios, we believe that there is substantial opportunity for STAR-0310 |
| Our ALPHA-STAR in HAE patients is progressing very well |
| So that's something that I think would differentiate us in terms of this drug's ability to impact meaningfully the lives of people with this disease |
| We are pleased to share that this trial is progressing well |
| The PK itself, I think, is a stronger supporter of potential effectiveness |
| Just a few days ago at ACAAI annual meeting, we shared positive Phase 1a data for STAR-0215 of our lead program that supports our vision for STAR-0215 to be the first choice preventative treatment for Hereditary Angioedema or HAE |
| So I think that our awareness amongst the top one KOLs is very high |
| We are pleased to see that this dosing regimen can maintain C-trop levels at about 25 micrograms per mil, well above the 12 microgram per mil threshold associated with prevention of HAE attacks |
| Here you see psoriasis demonstrates precedent for growth, for market growth and evolution for targeted therapies in dermatology |
| We just shared additional Phase 1a results at ACAAI this weekend, which further supports STAR-0215’s best-in-class PK profile, and the options for Q3 and Q6 month dosing as a potential HAE preventative therapy with robust attack suppression and low treatment burden |
| Statement |
|---|
| First of all, there potentially could be some perception as happens with dosing intervals with other products that you might be able to -- you might be losing some levels of efficacy as you extend the dose |
| Patients with HAE live in fear of having an attack that could be immensely painful or leave them disfigured for several days, or worse, could be fatal |
| So one, what are you hearing from payers or if you haven't gone there yet what's the work, you're thinking of doing there, preparing? Secondly, there still seem to be somewhat of a lack of awareness |
| And you pointed out one in question one, which is the lack of a placebo group, which for many is a detriment |
| Amlitelimab targets OX40-Ligand, which is expressed in a wider array of cell types, which could lead to increased risk for respiratory and vascular adverse events |
| So we believe that that might be an issue |
| T cell depletion leaves the cytokine release and potential increased risk of infection |
| And what quite a few patients, especially with Taxiro experience is injection site pain associated with the citrate buffer |
| The second issue is that the patients that had the six month dosing option had obviously two injections |
| Atopic dermatitis is an immune disorder associated with loss of skin barrier function and itching |
Please consider a small donation if you think this website provides you with relevant information